Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06412172 · ClinicalTrials.gov registry record
The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)
A clinical trial of Recurrent Respiratory Papillomatosis and Pulmonary Neoplasm, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT06412172: Recruiting study of Recurrent Respiratory Papillomatosis and Pulmonary Neoplasm, sponsored by Massachusetts General Hospital.
NCT06412172 is a study of Recurrent Respiratory Papillomatosis and Pulmonary Neoplasm that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, above the 22-participant average among 6 other Recurrent Respiratory Papillomatosis trials with a reported enrollment target (355% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06412172, a study of Recurrent Respiratory Papillomatosis and Pulmonary Neoplasm, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Recurrent respiratory papillomatosis (RRP) is an orphan disease that affects approximately 20,000 people in the United States and is caused by infection with human papillomavirus (HPV) types 6 and 11. Since RRP is an orphan disease, it is an understudied disease entity with correspondingly few treatment options. The investigators hypothesize that by understanding the biology of RRP and the failed host immune responses against HPV, novel and rational therapies can be developed. This study will examine the genetic and immunologic alterations found in these rare tumors and distant metastatic involved sites (such as the lung) in patients diagnosed with RRP.
Primary Outcome
HPV 6 and 11 genotyping will be done via polymerase chain reaction
Conditions Studied
Study Locations (1)
Connecticut
- Yale School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-04-15 |
| Est. Completion | 2030-04-15 |
What NCT06412172 shows while recruiting
NCT06412172 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 22-participant average among 6 other Recurrent Respiratory Papillomatosis trials with a reported enrollment target (355% higher).
The record links to 2 conditions, with Recurrent Respiratory Papillomatosis appearing as the primary indexed condition, and to 0 interventions.
NCT06412172 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06412172 about?
NCT06412172 is a clinical study titled "The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)". Recurrent respiratory papillomatosis (RRP) is an orphan disease that affects approximately 20,000 people in the United States and is caused by infection with human papillomavirus (HPV) types 6 and 11. Since RRP is an orphan disease, it is an understudied disease entity with correspondingly few treat...
What is the current status of trial NCT06412172?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-04-15. Estimated completion is 2030-04-15.
What conditions does trial NCT06412172 study?
This clinical trial studies the following conditions: Recurrent Respiratory Papillomatosis, Pulmonary Neoplasm.
Who is sponsoring clinical trial NCT06412172?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06412172 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Respiratory Papillomatosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zopa Retreatment and Vector Shedding in Adults With RRP
RECRUITING · Phase 4
-
Merck IIT: RRP Pembro and Lenvatinib
RECRUITING · Early Phase 1
-
Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients
RECRUITING · Phase 1
-
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
ACTIVE NOT RECRUITING · Phase 1
-
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
ACTIVE NOT RECRUITING · Phase 2
-
Avelumab for People With Recurrent Respiratory Papillomatosis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI